Back | Next |
home / stock / svra / svra message board
Subject | By | Source | When |
---|---|---|---|
I think $5 break is coming right up. | Hercules1 | investorshub | 12/30/2019 8:46:10 PM |
it is going to make a run to $5. | Hercules1 | investorshub | 12/30/2019 8:36:40 PM |
WOW smoking hot on FDA approval | Rocketred | investorshub | 12/30/2019 8:32:35 PM |
here we go people: | Hercules1 | investorshub | 12/30/2019 8:25:13 PM |
Looks like there will be a short squeeze | Hercules1 | investorshub | 12/30/2019 7:46:40 PM |
This is fixing to make another explosive jump. Can | Hercules1 | investorshub | 12/30/2019 7:17:58 PM |
Glad I waited until today. | boston127 | investorshub | 12/30/2019 4:02:45 PM |
Ofcourse imo | Roadtojourney | investorshub | 12/30/2019 3:27:25 PM |
Yup sell on news pos | Roadtojourney | investorshub | 12/30/2019 3:27:04 PM |
So...looks like the co. is funded. Yes!!! | Sage7243 | investorshub | 12/30/2019 3:15:25 PM |
Well, the ol' Balls O' Steel deliver another | davidsson10 | investorshub | 12/30/2019 2:43:13 PM |
Yes, saw that earlier..... | davidsson10 | investorshub | 12/30/2019 2:17:06 PM |
Savara Announces Private Placement of $26.8 Million, With | crudeoil24 | investorshub | 12/30/2019 2:13:10 PM |
Added | Liquid1974 | investorshub | 12/30/2019 1:58:56 PM |
* * $SVRA Video Chart 11-29-2019 * * | ClayTrader | investorshub | 11/29/2019 7:40:20 PM |
powercrush86: looks like a decent entry here just from all the recent downwind. Will see how this we | powercrush86 | investorshangout | 03/30/2017 9:19:49 PM |
J Scheid: who all is playing this thing? what do you think? I don't trust the CEO. But with the merg | J Scheid | investorshangout | 02/17/2017 11:03:01 PM |
PoemStone: $MSTX climb $0.472 | PoemStone | investorshangout | 06/28/2016 10:09:01 PM |
PoemStone: $MSTX at breakout $ | PoemStone | investorshangout | 06/22/2016 2:52:18 PM |
BooDog: $MSTX time to get some game on before topline data. | BooDog | investorshangout | 06/20/2016 12:38:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ra...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fir...
Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...